AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34342499 — intervention group
Group type: COMPARATOR
Intervention: CAC score <1000
Number of subjects: 309
Study 34342499 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC score ≥1000
Number of subjects: 309
Study 34342593 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention focusing on hypoglycemia education and symptom monitoring, including initial in-person visit, 3 weekly telecoaching calls, 1 biweekly call, and final in-person visit over 8 weeks.
Number of subjects: 40
Study 34342746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-120 mg/day)
Number of subjects: 49
Study 34342768 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva NAAT (three different protocols)
Number of subjects: 1452
Study 34342768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal Ag test
Number of subjects: 1452
Study 34342768 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal NAAT
Number of subjects: 1452
Study 34342846 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessment using SF-6D
Number of subjects: 120
Study 34342846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale (PCS)
Number of subjects: 120
Study 34342846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampa Scale for Kinesiophobia (TSK)
Number of subjects: 120
Study 34342846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Vigilance and Awareness Questionnaire (PVAQ)
Number of subjects: 120
Study 34343107 — intervention group
Group type: EXPERIMENTAL
Intervention: ROCHE Elecsys® immunoassay
Number of subjects: 911
Study 34343107 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMULITE-2000 immunoassay
Number of subjects: 911
Study 34343107 — intervention group
Group type: COMPARATOR
Intervention: Previous six immunoassays (iSYS, LIAISON XL, IMMULITE-2000 calibrated against IS 87/518, IGF-I RIACT, Mediagnost ELISA, Mediagnost RIA)
Number of subjects: 911
Study 34343107 — intervention group
Group type: EXPERIMENTAL
Intervention: All eight IGF-I assays
Number of subjects: 911
Study 34343142 — intervention group
Group type: EXPERIMENTAL
Intervention: Central blood pressure measurement using SphygmoCor System
Number of subjects: 501
Study 34343142 — intervention group
Group type: COMPARATOR
Intervention: Hypertension status
Number of subjects: 501
Study 34343142 — intervention group
Group type: COMPARATOR
Intervention: Diabetes status
Number of subjects: 501
Study 34343142 — intervention group
Group type: COMPARATOR
Intervention: Obesity status
Number of subjects: 501
Study 34343142 — intervention group
Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 501
Study 34343354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab 12 mg/kg weekly for up to four 28-day cycles
Number of subjects: 22
Study 34343443 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc treatment
Number of subjects: 704
Study 34343443 — intervention group
Group type: EXPERIMENTAL
Intervention: V3-loop CCR5-tropic sequences
Number of subjects: 704
Study 34343443 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate analysis of variants
Number of subjects: 704
Study 34343712 — intervention group
Group type: EXPERIMENTAL
Intervention: Degradable polymer film (DPF) inserted after hysteroscopic transcervical myoma resection
Number of subjects: 23
Study 34344169 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured RMR using indirect calorimetry
Number of subjects: 92
Study 34344169 — intervention group
Group type: COMPARATOR
Intervention: Predictive equations (Harris Benedict, Mifflin-St Jeor, WHO, Academy for Nutrition and Dietetics)
Number of subjects: 92
Study 34344717 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure (ΔP) on the first day of mechanical ventilation
Number of subjects: 1575
Study 34344717 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1575
Study 34344835 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal partial pressure of CO
Number of subjects: 25
Study 34344873 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled epichaperome probe administered by intravenous injection (single microdose)
Number of subjects: 0
Study 34345170 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Bronchitis (CB)
Number of subjects: 420
Study 34345170 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema (EM)
Number of subjects: 420
Study 34345718 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation and validation of the CRAFFT screening tool for alcohol use
Number of subjects: 3500
Study 34345718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional community household survey
Number of subjects: 3500
Study 34345718 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine samples collection for EtG measurement
Number of subjects: 3500
Study 34345718 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys and qualitative assessments in health and school systems
Number of subjects: 3500
Study 34345718 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with children
Number of subjects: 3500
Study 34346898 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual shopping experience
Number of subjects: 84
Study 34346898 — intervention group
Group type: COMPARATOR
Intervention: Cognitive challenge condition
Number of subjects: 84
Study 34346898 — intervention group
Group type: COMPARATOR
Intervention: Emotional challenge condition
Number of subjects: 84
Study 34346898 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 84
Study 34346900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy delivered via a smartphone mHealth app
Number of subjects: 60
Study 34346900 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 34347267 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime URLi
Number of subjects: 167
Study 34347267 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmeal URLi
Number of subjects: 167
Study 34347267 — intervention group
Group type: COMPARATOR
Intervention: Mealtime lispro
Number of subjects: 167
Study 34347504 — intervention group
Group type: EXPERIMENTAL
Intervention: New model for promoting widespread access to mental health care for depression and unhealthy alcohol use, utilizing mobile health technology.
Number of subjects: 0
Study 34347542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib with TOTEM (topotecan and temozolomide)
Number of subjects: 32
Study 34347542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib with everolimus
Number of subjects: 32
Study 34347859 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C <70 mg/dL
Number of subjects: 42378
Study 34347859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 42378
Study 34347859 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 42378
Study 34347859 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor vs. Clopidogrel
Number of subjects: 42378
Study 34347952 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 192
Study 34347952 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 192
Study 34348045 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34348230 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME (Peripheral Remodeling through Intermittent Muscular Exercise)
Number of subjects: 75
Study 34348230 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 75
Study 34348472 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Interventional Stroke Team (MIST)
Number of subjects: 226
Study 34348472 — intervention group
Group type: COMPARATOR
Intervention: Drip-and-ship (DS) model
Number of subjects: 226
Study 34348660 — intervention group
Group type: EXPERIMENTAL
Intervention: New primary care model including frailty screening, online portal for referrals, and tools for patient engagement and shared decision-making.
Number of subjects: 1600000
Study 34348660 — intervention group
Group type: COMPARATOR
Intervention: Usual care (baseline assessment).
Number of subjects: 1600000
Study 34348724 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant, antiaggregant, and anticoagulant plus antiaggregant drugs
Number of subjects: 451
Study 34348724 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of lung neoplasm
Number of subjects: 451
Study 34348724 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of bronchiectasis
Number of subjects: 451
Study 34348724 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 451
Study 34348724 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of haemoptysis
Number of subjects: 451
Study 34348797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation exposure
Number of subjects: 23
Study 34348797 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing for more than 14 days
Number of subjects: 23
Study 34348797 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-protective tidal volume
Number of subjects: 23
Study 34348797 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fluid balance
Number of subjects: 23
Study 34348797 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma D-dimers
Number of subjects: 23
Study 34348797 — intervention group
Group type: EXPERIMENTAL
Intervention: High ferritin levels
Number of subjects: 23
Study 34348889 — intervention group
Group type: EXPERIMENTAL
Intervention: electronically delivered cognitive behavioral therapy (e-CBT) for OCD, 16-week program
Number of subjects: 5
Study 34348918 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnT8A testing using age-related cut-offs
Number of subjects: 1704
Study 34348918 — intervention group
Group type: COMPARATOR
Intervention: Manufacturer's recommended threshold of 6 WHO U/mL
Number of subjects: 1704
Study 34348942 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise treatment algorithm based on BFI score
Number of subjects: 100
Study 34348942 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laxatives
Number of subjects: 100
Study 34348942 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripherally acting mu-opioid receptor antagonist (PAMORA)
Number of subjects: 100
Study 34348942 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMORA and conventional laxative
Number of subjects: 100
Study 34348950 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT) delivered in 10 sessions over 6 weeks with an accompanying home exercise programme (HEP)
Number of subjects: 24
Study 34348965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index/glycaemic load dietary patterns
Number of subjects: 1617
Study 34349004 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light chain (pNfL) levels in patients with genetic FTD/ALS
Number of subjects: 668
Study 34349004 — intervention group
Group type: COMPARATOR
Intervention: Plasma neurofilament light chain (pNfL) levels in controls
Number of subjects: 668
Study 34349026 — intervention group
Group type: EXPERIMENTAL
Intervention: CPL207280, a GPR40/FFA1 agonist; specific dosage and duration not mentioned
Number of subjects: 0
Study 34349026 — intervention group
Group type: COMPARATOR
Intervention: Control group; specific details not mentioned
Number of subjects: 0
Study 34349180 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-D,L-leucine
Number of subjects: 0
Study 34349180 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-leucine
Number of subjects: 0
Study 34349563 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic period (January 21 to July 31, 2020)
Number of subjects: 0
Study 34349563 — intervention group
Group type: COMPARATOR
Intervention: Pre-COVID-19 period (same period in 2019)
Number of subjects: 0
Study 34349716 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Ergometry intervention, details on dosage and duration not available
Number of subjects: 0
Study 34349716 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 34350144 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage (IM) delivered by parents at home
Number of subjects: 0
Study 34350300 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle (SB) ACLR
Number of subjects: 32
Study 34350300 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle plus lateral plasty (SBLP) ACLR
Number of subjects: 32
Study 34350300 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR (both techniques)
Number of subjects: 32
Study 34350455 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin (hs-cTn) based algorithms in anaemic patients
Number of subjects: 2223
Study 34350455 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin (hs-cTn) based algorithms in non-anaemic patients
Number of subjects: 2223
Study 34350455 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia as a predictor
Number of subjects: 2223
Study 34350455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb associated with hs-cTn
Number of subjects: 2223
Study 34350521 — intervention group
Group type: EXPERIMENTAL
Intervention: SHUEE
Number of subjects: 20
Study 34350582 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 7452
Study 34350730 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (mineralocorticoid blockade) for 8 weeks
Number of subjects: 13
Study 34350730 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=10; male/female, Caucasians)
Number of subjects: 13
Study 34350814 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention aimed at introducing more traditional AN subsistence foods, increasing fruit and vegetable intake, and decreasing sugar-sweetened beverage (SSB) consumption.
Number of subjects: 22
Study 34350827 — intervention group
Group type: EXPERIMENTAL
Intervention: T-REX machine learning workflow
Number of subjects: 0
Study 34350976 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 2750
Study 34351368 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-intensive therapies
Number of subjects: 1987
Study 34351368 — intervention group
Group type: COMPARATOR
Intervention: Intensive therapies
Number of subjects: 1987
Study 34351679 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-Positive Donor to a SARS-CoV-2-Positive Recipient
Number of subjects: 0
Study 34351867 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Check-Up for Expectant Moms (HCEM) intervention
Number of subjects: 136
Study 34351867 — intervention group
Group type: COMPARATOR
Intervention: In-person recruitment
Number of subjects: 136
Study 34352143 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation-brush-irrigation (test) with chlorhexidine (0.2%)
Number of subjects: 20
Study 34352143 — intervention group
Group type: COMPARATOR
Intervention: Repeated irrigation alone (control)
Number of subjects: 20
Study 34352165 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-Generation Antipsychotics
Number of subjects: 0
Study 34352165 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34352166 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid Burden
Number of subjects: 0
Study 34352386 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coach-delivered single session + portal-like messaging via web portal over 30 days
Number of subjects: 0
Study 34352386 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coach-delivered single session + enhanced usual care (EUC)
Number of subjects: 0
Study 34352386 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) + portal-like messaging via web portal over 30 days
Number of subjects: 0
Study 34352386 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) + enhanced usual care (EUC)
Number of subjects: 0
Study 34352736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical microelectrode array
Number of subjects: 0
Study 34352736 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 34352834 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid ART initiation (within 7 days of HIV diagnosis)
Number of subjects: 350
Study 34352834 — intervention group
Group type: COMPARATOR
Intervention: Standard ART initiation (not specifically defined, but initiated as soon as possible)
Number of subjects: 350
Study 34352924 — intervention group
Group type: EXPERIMENTAL
Intervention: Retosiban
Number of subjects: 98
Study 34352924 — intervention group
Group type: COMPARATOR
Intervention: Comparator (placebo/atosiban)
Number of subjects: 98
Study 34352935 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer-based thermosensitive sol-gel (PTAS) agent applied to the operative field after ALND
Number of subjects: 170
Study 34352935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no poloxamer applied)
Number of subjects: 170
Study 34353122 — intervention group
Group type: EXPERIMENTAL
Intervention: SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems
Number of subjects: 0
Study 34353122 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34353317 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 186
Study 34353599 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-IMR >40 U
Number of subjects: 340
Study 34353599 — intervention group
Group type: COMPARATOR
Intervention: Angio-IMR ≤40 U
Number of subjects: 340
Study 34353599 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-IMR
Number of subjects: 340
Study 34353802 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided group
Number of subjects: 500
Study 34353802 — intervention group
Group type: COMPARATOR
Intervention: GOLD guideline-guided group
Number of subjects: 500
Study 34353808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin 2 g/4-hour intravenous plus fosfomycin 3 g/6-hour intravenous for 7 days
Number of subjects: 183
Study 34353808 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin 2 g/4-hour intravenous alone for 7 days
Number of subjects: 183
Study 34353822 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition upper gastrointestinal (GI) endoscopy without magnification
Number of subjects: 153
Study 34353822 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 153
Study 34353848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 137
Study 34353986 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent hypoparathyroidism
Number of subjects: 141
Study 34354225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T) at 0.3 mg/kg every 6 weeks for two cycles
Number of subjects: 200
Study 34354225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T) at 0.3 mg/kg every 6 weeks
Number of subjects: 200
Study 34354626 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34354735 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic protocol including multiple ligation-dependent probe amplification for copy number variation (CNV) detection
Number of subjects: 67
Study 34354920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab (TAFA) plus lenalidomide (LEN)
Number of subjects: 0
Study 34354920 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Number of subjects: 0
Study 34355001 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive End-Expiratory Pressure (PEEP) strategies
Number of subjects: 0
Study 34355001 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 34355155 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g/day of inulin (prebiotic) supplementation
Number of subjects: 48
Study 34355155 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo) supplementation
Number of subjects: 48
Study 34355278 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal SARS-CoV-2 infection during pregnancy
Number of subjects: 56
Study 34355278 — intervention group
Group type: COMPARATOR
Intervention: History of SARS-CoV-2 infection prior to gestational week 12
Number of subjects: 56
Study 34355282 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 0
Study 34355282 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study 34355282 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study 34355354 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen (continuous weekly treatment)
Number of subjects: 135
Study 34355354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to inotersen at OLE study baseline)
Number of subjects: 135
Study 34355741 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PD-L1(+) circulating tumor cells (CTCs) detected with CellSearch® system
Number of subjects: 54
Study 34355741 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PD-L1(+) CTCs
Number of subjects: 54
Study 34355741 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of gene alterations, number of metastatic sites, prior systemic therapies, presence of CTCs and PD-L1(+) CTCs
Number of subjects: 54
Study 34355741 — intervention group
Group type: EXPERIMENTAL
Intervention: Squamous cell carcinoma histology, number of prior systemic treatments, presence of CTC
Number of subjects: 54
Study 34355741 — intervention group
Group type: COMPARATOR
Intervention: PD-L1 expression in tumor tissue
Number of subjects: 54
Study 34356039 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed sarcopenia (LMM adjusted for BMI)
Number of subjects: 81
Study 34356039 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable sarcopenia
Number of subjects: 81
Study 34356039 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed sarcopenia (LMM adjusted for height2)
Number of subjects: 81
Study 34356039 — intervention group
Group type: EXPERIMENTAL
Intervention: Age in patients with probable sarcopenia
Number of subjects: 81
Study 34356039 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke duration in patients with probable or confirmed sarcopenia
Number of subjects: 81